{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:44:36Z","timestamp":1788414276466,"version":"build-2803163510"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672133 81874010"],"award-info":[{"award-number":["81672133 81874010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antiresorptive drugs have been widely used for osteoporosis. Intermittent parathyroid hormone (PTH), an anabolic agent, increases osteoblast production rate and inhibits apoptosis of osteoblasts, thus increasing skeletal mass besides improving bone microarchitecture and strength. Combination therapy for osteoporosis produced great interests and controversies. Therefore, we performed a systematic literature search from PubMed, EMBASE, Scopus, Web of Science, CINDHL, and the Cochrane Database of Systematic Reviews using the search terms PTH or teriparatide combined with bisphosphonate, alendronate, ibandronate, risedronate, raloxifene, denosumab, and zoledronic acid with the limit osteoporosis. At last, 36 related articles were included for further analysis. Findings from previous studies revealed that combination therapy in different conditions of naive or previous bisphosphonate treatment might have different outcomes. The use of combination therapy, however, may be an alternative option among osteoporotic patients with a history of bisphosphonate use. Combined teriparatide with denosumab appear to show the most substantial and clinically relevant skeletal benefits to osteoporotic patients. Additional research is necessary to define optimal methods of developing sequential and\/or cyclical combinations of PTH and antiresorptive agents.<\/jats:p>","DOI":"10.3389\/fphar.2020.607017","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T04:56:55Z","timestamp":1611723415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives"],"prefix":"10.3389","volume":"11","author":[{"given":"Chenggui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"0110041","DOI":"10.1115\/1.4028823","article-title":"Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone","volume":"137","author":"Altman","year":"2015","journal-title":"J. Biomech. Eng"},{"key":"B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2014.01.008","article-title":"A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment","volume":"61","author":"Altman","year":"2014","journal-title":"Bone"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2018.11.010","article-title":"New therapeutic targets for osteoporosis","volume":"120","author":"Anagnostis","year":"2019","journal-title":"Maturitas"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J. Bone Miner. Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expet Opin. Pharmacother"},{"key":"B6","first-page":"79","article-title":"[Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies]","volume":"114","author":"Arboleya","year":"2000","journal-title":"Med. Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00223-010-9390-z","article-title":"Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy","volume":"87","author":"Arrington","year":"2010","journal-title":"Calcif. Tissue Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2017.8040","article-title":"Association between alendronate use and hip fracture risk in older patients using oral prednisolone","volume":"318","author":"Axelsson","year":"2017","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","journal-title":"J. Bone Miner. Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bone.2011.04.008","article-title":"The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat","volume":"49","author":"Campbell","year":"2011","journal-title":"Bone"},{"key":"B13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","article-title":"New Frontiers in osteoporosis therapy","volume":"71","author":"Cheng","year":"2020","journal-title":"Annu. Rev. Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/bonekey.2014.13","article-title":"Combination therapy for osteoporosis: a reappraisal","volume":"3","author":"Cosman","year":"","journal-title":"BoneKEy Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman","year":"","journal-title":"Curr. Osteoporos. Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J. Bone Miner. Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jbmr.3850","article-title":"Standard versus cyclic teriparatide and denosumab treatment for osteoporosis: a randomized trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J. Bone Miner. Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J. Bone Miner. Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"Cosman","year":"1998","journal-title":"J. Bone Miner. Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","article-title":"Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy","volume":"19","author":"Cosman","year":"2008","journal-title":"Osteoporos. Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ecl.2012.04.005","article-title":"Combination anabolic and antiresorptive therapy for osteoporosis","volume":"41","author":"Cusano","year":"2012","journal-title":"Endocrinol Metab. Clin. N. Am"},{"key":"B26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bone.2014.12.061","article-title":"muCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy","volume":"73","author":"de Bakker","year":"2015","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J. Bone Miner. Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-r","article-title":"The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate\u2014is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?","volume":"16","author":"Delmas","year":"1995","journal-title":"Bone"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/jbmr.2822","article-title":"Effects of daily or cyclic teriparatide on bone formation in the iliac crest in women on no prior therapy and in women on alendronate","volume":"31","author":"Dempster","year":"","journal-title":"J. Bone Miner. Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/jbmr.2825","article-title":"Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 Months in the SHOTZ study","volume":"31","author":"Dempster","year":"","journal-title":"J. Bone Miner. Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bone.2013.02.004","article-title":"Proposed pathogenesis for atypical femoral fractures: lessons from materials research","volume":"55","author":"Ettinger","year":"2013","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/JBMR.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J. Bone Miner. Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bone.2016.05.004","article-title":"Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment","volume":"89","author":"Fahrleitner-Pammer","year":"2016","journal-title":"Bone"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.2174\/1381612823666170713104431","article-title":"New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application","volume":"23","author":"Fassio","year":"2017","journal-title":"Curr. Pharmaceut. Des"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11154-006-9007-z","article-title":"The use of parathyroid hormone in the treatment of osteoporosis","volume":"7","author":"Girotra","year":"2006","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/s8756-3282(01)00673-1","article-title":"Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation","volume":"30","author":"Guo","year":"2002","journal-title":"Bone"},{"key":"B41","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr. Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1177\/00220345000790061301","article-title":"Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone","volume":"79","author":"Hunziker","year":"2000","journal-title":"J. Dent. Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","article-title":"Teriparatide and denosumab combination therapy and skeletal metabolism","volume":"27","author":"Idolazzi","year":"2016","journal-title":"Osteoporos. Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1210\/en.2007-0229","article-title":"The effects of combination of alendronate and human parathyroid hormone (1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL\/6J mice","volume":"148","author":"Johnston","year":"2007","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1359\/jbmr.080805","article-title":"Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans","volume":"23","author":"Keaveny","year":"2008","journal-title":"J. Bone Miner. Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/med.0000000000000507","article-title":"Combination therapies in the treatment of osteoporosis","volume":"26","author":"Kelly","year":"2019","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes"},{"key":"B47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrendo.2011.108","article-title":"Parathyroid hormone analogues in the treatment of osteoporosis","volume":"7","author":"Kraenzlin","year":"2011","journal-title":"Nat. Rev. Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the data extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/8756-3282(95)00115-t","article-title":"Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats","volume":"16","author":"Li","year":"1995","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00198-011-1751-6","article-title":"The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats","volume":"23","author":"Li","year":"2012","journal-title":"Osteoporos. Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J. Bone Miner. Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e015187","DOI":"10.1136\/bmjopen-2016-015187","article-title":"Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials","volume":"8","author":"Lou","year":"2018","journal-title":"BMJ Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos. Int"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1210\/en.2002-221061","article-title":"New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats","volume":"144","author":"Ma","year":"2003","journal-title":"Endocrinology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1359\/jbmr.060314","article-title":"Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis","volume":"21","author":"Ma","year":"2006","journal-title":"J. Bone Miner. Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","article-title":"Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment","volume":"59","author":"Ma","year":"2014","journal-title":"Bone"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.11005\/jbm.2014.21.1.8","article-title":"Bone biology and anabolic therapies for bone: current status and future prospects","volume":"21","author":"Martin","year":"2014","journal-title":"J Bone Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/s8756-3282(01)00433-1","article-title":"Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"B63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/bf01771800","article-title":"Effects of single and concurrent intermittent administration of human parathyroid hormone and bisphosphonate cimadronate on bone mineral densities of femur in ovariectomized rats","volume":"13","author":"Mashiba","year":"1995","journal-title":"J. Bone Miner. Metabol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11914-017-0376-x","article-title":"Using osteoporosis therapies in combination","volume":"15","author":"McClung","year":"2017","journal-title":"Curr. Osteoporos. Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J. Bone Miner. Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.tem.2015.01.004","article-title":"Anabolic effects of PTH and the \u201canabolic window","volume":"26","author":"Pazianas","year":"2015","journal-title":"Trends Endocrinol. Metabol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"28164","DOI":"10.1074\/jbc.M110.101964","article-title":"Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL","volume":"285","author":"Pierroz","year":"2010","journal-title":"J. Biol. Chem"},{"key":"B70","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1210\/clinem\/dgz163","article-title":"Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT","volume":"105","author":"Ramchand","year":"","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4161","article-title":"Effects of combination denosumab and high-dose teriparatide administration on bone microarchitecture and estimated strength: the DATA-HD HR-pQCT study","author":"Ramchand","year":"","journal-title":"J. Bone Miner. Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J. Bone Miner. Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1210\/jc.2012-1844","article-title":"Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial","volume":"97","author":"Schafer","year":"2012","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B75","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jbmr.2496","article-title":"Co-administration of antiresorptive and anabolic agents: a missed opportunity","volume":"30","author":"Seeman","year":"2015","journal-title":"J. Bone Miner. Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00198-007-0336-x","article-title":"Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis","volume":"18","author":"Sellmeyer","year":"2007","journal-title":"Osteoporos. Int"},{"key":"B77","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ecl.2016.09.008","article-title":"Combined pharmacologic therapy in postmenopausal osteoporosis","volume":"46","author":"Shen","year":"2017","journal-title":"Endocrinol Metab. Clin. N. Am"},{"key":"B78","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.nano.2012.12.003","article-title":"Novel biodegradable electrospun nanofibrous P(DLLA-CL) balloons for the treatment of vertebral compression fractures","volume":"9","author":"Sun","year":"2013","journal-title":"Nanomedicine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br. J. Clin. Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00418-016-1450-7","article-title":"Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice","volume":"146","author":"Tsuboi","year":"2016","journal-title":"Histochem. Cell Biol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bone.2014.06.020","article-title":"Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats","volume":"66","author":"Vegger","year":"2014","journal-title":"Bone"},{"key":"B84","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cclet.2019.07.033","article-title":"Resorbable polymer electrospun nanofibers: history, shapes and application for tissue engineering","volume":"31","author":"Wu","year":"2020","journal-title":"Chin. Chem. Lett"},{"key":"B86","doi-asserted-by":"publisher","first-page":"14952","DOI":"10.1021\/am502716t","article-title":"3D artificial bones for bone repair prepared by computed tomography-guided fused deposition modeling for bone repair","volume":"6","author":"Xu","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.bone.2008.05.010","article-title":"The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice","volume":"44","author":"Yamane","year":"2009","journal-title":"Bone"},{"key":"B88","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bone.2012.09.039","article-title":"Positive alterations of viscoelastic and geometric properties in ovariectomized rat femurs with concurrent administration of ibandronate and PTH","volume":"52","author":"Yang","year":"2013","journal-title":"Bone"},{"key":"B89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1620\/tjem.186.131","article-title":"Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats","volume":"186","author":"Zhang","year":"1998","journal-title":"Tohoku J. Exp. Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/08941939","article-title":"Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2015","journal-title":"J. Invest. Surg"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1039\/c9bm01655d","article-title":"Improved osseointegration with rhBMP-2 intraoperatively loaded in a specifically designed 3D-printed porous Ti6Al4V vertebral implant","volume":"8","author":"Zhang","year":"","journal-title":"Biomater. Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1039\/d0bm00361a","article-title":"3D printed porous titanium cages filled with simvastatin hydrogel promotes bone ingrowth and spinal fusion in rhesus macaques","volume":"8","author":"Zhang","year":"","journal-title":"Biomater. Sci"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.607017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T04:56:59Z","timestamp":1611723419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.607017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":92,"alternative-id":["10.3389\/fphar.2020.607017"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.607017","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"article-number":"607017"}}